Discordant expression of the cyclin-dependent kinases and cyclins and rat liver following acute administration of the hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643)

Biochemical Pharmacology

Volumn 52, Issue 11, 1996, Pages 1749-1755

  Rininger, Joseph A ^a,b   Wheelock, Geoffrey D ^a   Ma, Xinfang ^a   Babish, John G ^a,b  

^a Cornell Technology Park ^*  (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

cell cycle; cyclin dependent kinase; hepatocarcinogenesis; peroxisome proliferator

Indexed keywords

ANTILIPEMIC AGENT; CARCINOGEN; CYCLIN B; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLINE; LIVER PROTEIN; PEROXISOME PROLIFERATOR; PIRINIXIC ACID; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE PHASE; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CHROMATOGRAPHY; CONTROLLED STUDY; GEL FILTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CARCINOGENESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CARCINOGENS; CYCLIN-DEPENDENT KINASES; CYCLINS; LIVER; MALE; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030582836     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00596-5     Document Type: Article

References (42)

1. 1. Green S, Tugwood JD and Issemann I, The molecular mechanism of peroxisome proliferates action: A model for species differences and mechanistic risk assessment. Toxicol Lett 64/ 65: 131-139, 1992.
2. 2. Sher T, Yi H-F, McBride OW and Gonzalez FJ, cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32: 5598-5604, 1993.
3. 3. Bartles JR, Khuon S, Lin X, Zhang L, Reddy JK, Rao MS, Osoye ST, Nehme CL and Fayos BE, Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins. Cancer Res 50: 669-676, 1990.
4. 4. Muerhoff AS, Griffin KJ and Johnson EF, The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J Biol Chem 267: 19051-19053, 1992.
5. 5. Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM, Convergence of 9-cis retinoic acid and peroxisome proliferative signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774, 1992.
6. 6. Chen N and Crane DI, Induction of the major integral membrane protein of mouse liver peroxisomes by peroxisome proliferators. Biochem J 283: 605-610, 1992.
7. 7. Ma X, Mufti NA and Babish JG, Protein tyrosine phosphorylacion as an indicator of 2,3,7,8-tetrachloro-p-dioxin exposure in vivo and in vitro. Biochem Biophys Res Commun 189: 59-65, 1992.
8. 8. Wada N, Marsman DS and Popp JA, Dose-related effects of the hepatocarcinogen, WY-14,643 on peroxisomes and cell replication. Fundam Appl Toxicol 18: 149-154, 1992.
9. 9. Busser M-T and Lutz WK, Stimulation of DNA synthesis in rat and mouse liver by various tumor promoters. Carcinogenesis 8: 1433-1437, 1987.
10. 10. Marsman DS, Cattley RC, Conway JG and Popp JA, Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the heaptocarcinogenicity of the peroxisome proliferators di-(2-ethylhexyl)phthalate and [4-chloro6-(2,3-xylidino)-2]-pyrimidinylthio]acetic acid (WY-14,643) in rats. Cancer Res 48, 6739-6744, 1988.
11. 11. Eacho PI, Lanier TL and Brodhecker CA, Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: Comparison of WY14-14,643 to clofibric acid, nafenopin, and LY171883. Carcinogenesis 12: 1557-1561, 1991.
12. 12. Kamb A, Cell cycle regulators and cancer. Trends Genet 11: 136-140, 1995.
13. 13. Hartwell LH and Kastan MB, Cell cycle control and cancer. Science 266: 1821-1828, 1994.
14. 14. Draetta G, Mammalian G1 cyclins. Curr Opin Cell Biol 6: 842-846, 1994.
15. 15. King RW, Jackson PK and Kirschner MW, Mitosis in transition. Cell 79: 563-571, 1994.
16. 16. Nurse P, Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994.
17. 17. Sherr CJ, G1 phase progression; cycling on cue. Cell 79: 551-555, 1994.
18. 18. Heichman KA and Roberts JM, Rules to replicate by. Cell 79: 557-562, 1994.
19. 19. Hunter T and Pines J, Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
20. 20. Nigg EA, Cellular substrates of p34cdc2 and its companion cyclin dependent kinases. Trends Cell Biol 3: 296-301, 1993.
21. 21. Pines J, The cell cycle kinases. Semin Cancer Biol 5: 305-313, 1994.
22. 22. Loyer P, Glaise D, Cariou S, Baffet G, Meijer L and Guguen-Guillouzo C, Expression and activation of CDKs (1 and 2) and cyclins in the cell cycle progression during liver regeneration. J Biol Chem 269: 2491-2500, 1994.
23. 23. Albrecht JH, Hoffman JS, Kren BS and Steer CJ, Cyclin and cyclin-dependent kinase 1 mRNA expression in models of regenerating liver and human diseases. Am J Physiol 265: G857-G864, 1993.
24. 24. Lu XP, Koch KS, Lew DJ, Dulic V, Pines J, Reed SI, Hunter T and Leffert HL, Induction of cyclin mRNA and cyclin-associated histone H1 kinase during liver regeneration. J Biol Chem 267: 2841-2844, 1992.
25. 25. Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y and Griffin JD, cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 250: 805-808, 1990.
26. 26. Wolowiec D, Deviller P, Simonin D, Souchier C, Rimokh R, Benchaib M, Bryon P-A and Ffrench M, CDK1 is a marker of proliferation in human lymphoid cells. Int J Cancer 61: 381-388, 1995.
27. 27. Ma X and Babish JG, Acute 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure results in enhanced tyrosylphosphorylation and expression of murine hepatic cyclin dependent kinases. Biochem Biophys Res Commun 197: 1070-1077, 1993.
28. 28. Ma X, Stoffregen D, Wheelock GD, Rininger J and Babish JG, Acute dosing of the hepatocarcinogen [4-chloro-6-(2,3,-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643) to rats results in enhanced hepatic expression of the cell division control enzyme p34cdc2 kinase. Mol Pharmacol, in press, 1996.
29. 29. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
30. 30. Towbin H, Staehelin T and Gordon J, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
31. 31. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A and Weinberg RA, Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993.
32. 32. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y and Livingston DM, Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497, 1993.
33. 33. Albrecht JH, Hu MY and Cerra FB, Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver. Biochem Biophys Res Commun 209: 648-655, 1995.
34. 34. Yasui W, Ayhan A, Kitadai Y, Nishimura K, Yokozaki H, Ito H and Tahara E, Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 53: 36-41, 1993.
35. 35. Keyomarsi K and Pardee AB, Redundent cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90: 1112-1116, 1993.
36. 36. Xiong Y, Zhang H and Beach D, D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992.
37. 37. Zhang H, Xiong Y and Beach D, Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897-906, 1993.
38. 38. Dietrich DR, Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit Rev Toxicol 23: 77-109, 1993.
39. 39. Szepesi A, Gelfand EW and Lucas JJ, Association of proliferating cell nuclear antigen with cyclin-dependent kinases and cyclins in normal and transformed human T lymphocytes. Blood 84: 3413-3421, 1994.
40. 40. Enan E and Matsumura F, Evidence for a second pathway in the action mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Biochem Pharmacol 49: 249-261, 1994.
41. 41. Cayama E, Tsuda H, Sarma DSR and Farber E, Initiation of chemical carcinogenesis requires cell proliferation. Nature 275: 60-62, 1978.
42. 42. Schulte-Hermann R, Tumor promotion in the liver. Arch Toxicol 57: 147-158, 1985.